About Us
Corporate Overview
Product Pipeline
In-Licensing/Product Acquisition
Management
Board of Directors
Product candidate
Target indication
Development status
KRX-0401
(perifosine)
Multiple myeloma
Colorectal cancer
Multiple other forms of cancer
Phase 3 ongoing, under SPA
Phase 3 ongoing, under SPA
Phase 2 trials ongoing
Zerenex
TM
(ferric citrate)
Hyperphosphatemia
in patients with end-stage renal disease
U.S. Phase 3 program ongoing under SPA;
Japan Phase 2 complete by sublicensee (JT and Torii)
Copyright © 2010 by Keryx Biopharmaceuticals, Inc.
Update Notice
|
Disclaimer
|
Contact Us